Holen Sie sich die Stockscreener-App
1.68
3.07%
0.05
Dare Bioscience Inc Aktie (DARE) Neueste Nachrichten
Dare Bioscience (NASDAQ:DARE) Stock Passes Below 200-Day Moving Average – What’s Next? - Defense World
Daré targets DARE to PLAY launch in December 2025 as dual path strategy accelerates - MSN
Dare Bioscience Inc (DARE) Q3 2025 Earnings Call Highlights: Str - GuruFocus
Dare Bioscience Inc (DARE) Q3 2025 Earnings Call Highlights: Strategic Advances and Financial ... - Yahoo Finance
Daré Bioscience (DARE) Q3 2025 Earnings Transcript - AOL.com
Transcript : Daré Bioscience, Inc., Q3 2025 Earnings Call, Nov 13, 2025 - MarketScreener
Earnings call transcript: Dare Bioscience Q3 2025 sees mixed stock reaction - Investing.com Nigeria
Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
DARE Bioscience Prepares for Launch of Sildenafil Cream - GuruFocus
Daré Bioscience Reports Third Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
Daré Bioscience Q3 2025 Financial Results and Corporate Update - TradingView
Daré (NASDAQ: DARE) to launch DARE to PLAY Sildenafil Cream in December via 503B pathway - Stock Titan
Caribou Biosciences, Inc. (CRBU) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
What to Expect from Dare Bioscience's Earnings - Benzinga
Earnings To Watch: Dare Bioscience Inc (DARE) Reports Q3 2025 Re - GuruFocus
Earnings To Watch: Dare Bioscience Inc (DARE) Reports Q3 2025 Result - Yahoo Finance
Dare Bioscience Highlights Commercial Launch Readiness for DARE to PLAY Sildenafil Cream, November 17th Webinar to Feature Leading Clinicians Discussing Clinical Data and Potential Impact in Women's Sexual Health - MarketScreener
Multi asset correlation models including Daré Bioscience Inc.Product Launch & AI Powered Market Entry Ideas - newser.com
Dare Bioscience (DARE) to Host Webinar on Innovative Sildenafil Cream - GuruFocus
Daré Bioscience (NASDAQ: DARE) plans 503B availability for DARE to PLAY before year-end - Stock Titan
Daré Bioscience to Host Third Quarter 2025 Financial Results and Company Update Conference Call and Webcast on November 13, 2025 - The Manila Times
Daré Bioscience to Host Third Quarter 2025 Financial - GlobeNewswire
Daré Bioscience (NASDAQ: DARE) hosts financial results call Nov 13 at 4:30 p.m. ET - Stock Titan
Dare Bioscience (DARE) to Release Earnings on Thursday - Defense World
Daré Bioscience to Receive up to $300,000 to Conduct Global Contraceptive Innovation Capabilities Landscape Assessment - The Manila Times
Dare Bioscience to Receive Up to $300,000 to Conduct Global Contraceptive Innovation Capabilities Landscape Assessment - MarketScreener
Will Daré Bioscience Inc. stock sustain high P E ratiosPortfolio Value Summary & Weekly Market Pulse Updates - newser.com
Daré Bioscience receives $4 million grant installment for contraceptive device By Investing.com - Investing.com Nigeria
Daré Bioscience Receives $4 Million Non-Dilutive Grant - GlobeNewswire
Law Custodial Inc. Files Schedule 13G Showing 1.41M DARE Shares - Stock Titan
Dare Bioscience (DARE) Secures $4M for Long-Acting Contraceptive Development - GuruFocus
Daré Bioscience receives $4 million grant installment for contraceptive device - Investing.com India
Daré Bioscience Receives $4 Million Non-Dilutive Grant Installment; Total of $41.8M Received to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic - GlobeNewswire
$41.8M Received to Date — Daré Bioscience Advances DARE-IDDS Contraception Program, Seeks Partners - Stock Titan
Daré Bioscience enters into $15M stock purchase agreement - MSN
Dare Bioscience risks Nasdaq delisting over market value - MSN
DARE Secures Gates Foundation Funding for Preeclampsia Projects - GuruFocus
Daré Bioscience, Inc. Secures $499,000 Grant from Gates Foundation to Address Preeclampsia in Women's Health - Quiver Quantitative
Daré Bioscience to Receive up to $499,000 to Support Preeclampsia Research - GlobeNewswire
76,000 Maternal Deaths Annually: Daré Bioscience Receives Gates Grant to Combat Preeclampsia Crisis - Stock Titan
Dare Bioscience (NASDAQ:DARE) Shares Pass Below 200 Day Moving Average – What’s Next? - Defense World
Daré Bioscience targets Q4 2025 launch for DARE to PLAY Sildenafil cream while advancing dual-path strategy - MSN
Dare Bioscience files to sell 2.75M shares of common stocks by selling shareholders - MSN
What’s the recovery path for long term holders of Daré Bioscience Inc.Inflation Watch & Low Drawdown Investment Ideas - newser.com
Using Python tools to backtest Daré Bioscience Inc. strategies2025 Price Action Summary & Comprehensive Market Scan Insights - Newser
Maxim upgrades Daré Bioscience on extended cash runway, commercial launch - TradingView
Maxim Group upgrades Dare Bioscience stock to Buy on funding boost - Investing.com Canada
Dare Bioscience (DARE) Upgraded to Buy by Maxim Group | DARE Sto - GuruFocus
Dare Bioscience shares rise 4.37% premarket after Maxim upgraded to Buy from Hold. - AInvest
Dare Bioscience: Maxim Group upgrades Buy from Hold, PT $8. - AInvest
Maxim Upgrades Dare Bioscience to Buy From Hold, Price Target is $8 - MarketScreener
This Brinker International Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday - Benzinga
Daré Bioscience Engages Market with New Presentation - TipRanks
Daré Bioscience, Inc. (NASDAQ:DARE) Q2 2025 Earnings Call Transcript - MSN
Pattern recognition hints at Daré Bioscience Inc. upsideQuarterly Trade Review & Long-Term Safe Investment Ideas - Newser
Brookline Capital Markets Sticks to Their Buy Rating for Daré Bioscience (DARE) - The Globe and Mail
1.38%
1.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):